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Pruritus is an important symptom frequently accompanying various inflammatory skin conditions. Some recent data have indicated
that it may also be associated with autoimmune connective tissue diseases, including systemic sclerosis and dermatomyositis;
however, studies on the prevalence and clinical characteristics of pruritus in CLE are limited. We have performed a multinational,
prospective, cross-sectional study in order to assess the prevalence and intensity of pruritus in adult patients suffering from
various subtypes of CLE. After developing a questionnaire assessing various aspects of pruritus, we have surveyed 567 patients
with cutaneous involvement during the course of LE regarding the presence and intensity of pruritus. Pruritus was present in 425
of all patients (75.0%) and was most frequently reported by subjects with acute CLE (82.1%), followed by chronic CLE (78.8%),
subacute CLE (65.9%), and intermittent CLE (55.6%) (p<0.001). Based on the Numerical Rating Scale, the severity of itch was mild,
moderate, and severe in 264 (62.1%), 98 (23.1%), and 63 (14.8%) patients, respectively. The highest mean pruritus intensity was
reported by subjects with hypertrophic LE (5.1 ± 3.0 points) followed by generalized discoid LE (3.6 ± 3.0 points), subacute CLE
(3.0 ± 3.0 points), chilblain LE (3.0 ± 1.0 points), localized discoid LE (2.6 ± 2.0 points), intermittent CLE (2.6 ± 3.0 points), acute
CLE (2.5 ± 1.2 points), and lupus erythematosus profundus (1.9 ± 2.7 points). In conclusion, pruritus is a frequent phenomenon
in CLE; however, in most patients it is of mild severity. Further studies are needed to better characterize its clinical characteristics
and influence on patients’ well-being.
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1. Introduction
Cutaneous lupus erythematosus (CLE) is an autoimmune
condition encompassing a wide range of dermatologic man-
ifestations. Skin involvement in CLE patients can be divided
into two categories based on histology: lupus erythematosus-
(LE-) specific and LE-nonspecific skin lesions. The presence
of LE-specific lesions is necessary to confirm the diagnosis
of CLE. LE-specific skin lesions are divided into several
subtypes based on clinical characteristics: acute CLE (ACLE),
subacute CLE (SCLE), and chronic CLE (CCLE) with several
variants including discoid LE (DLE), presenting as a localized
or generalized form, LE profundus (LEP) (also called lupus
panniculitis or subcutaneous LE), hypertrophic LE (HLE),
chilblain LE (CHLE), and lupus erythematosus tumidus
(LET) [1]. Some authors consider LET as a distinct subtype,
namely, intermittent CLE (ICLE) [2]; thus, this subtype was
considered separately in our analysis.
Pruritus is defined as an unpleasant sensation causing
a desire to scratch [3]. Pruritus is regarded as the most
prevalent subjective symptom in dermatology reported by
more than half of the patients with skin disorders [4]. Its
high prevalence in certain dermatological conditions, such
as atopic dermatitis or urticaria, has been widely confirmed
and thoroughly investigated in terms of quantitative and
qualitative measures [5, 6]. In some other very common skin
disorders like psoriasis, it was only recent years that con-
firmed its actual importance in terms of high prevalence and
marked impact on patients’ quality of life (QoL) [7]. A recent
data suggests that itch may also be a common component of
autoimmune connective tissue diseases, including systemic
sclerosis (SSc) and dermatomyositis (DM) [8–10]. However,
studies on the true prevalence and clinical characteristics
of pruritus in CLE are very limited and bring ambiguous
results. Discrepancies between various studies that included
itch evaluation in LE patients with cutaneous involvement
may suggest that, without adequate investigation by medical
personnel, the presence of this bothersome symptom could
easily be underestimated or even missed. Therefore, we
performed a multinational, multicenter study to precisely
assess the prevalence and clinical characteristics of pruritus
in different variants of CLE in relation to skin lesion spec-
trum.
2. Methods
A multinational, multicenter, prospective, cross-sectional
study was conducted in order to determine the prevalence
of pruritus and assess its intensity and clinical characteristics
in adult patients suffering from various subtypes of CLE.
Centers from various continents with special interest and
experience in CLE diagnostics and treatment were selected
to cover possible racial and environmental differences: 6
centers from 3 countries in Europe (France, Italy, Poland),
5 centers from 2 countries in Asia (Japan, Bangladesh), and
1 center from North America (Pennsylvania). The study
was conducted in accordance with the Data Protection Act
and according to the ethical guidelines of the Declaration
of Helsinki and was approved by the Ethics Committee at
Wroclaw Medical University in Poland.
2.1. Patients. A total number of 567 inpatients and outpa-
tients of aforementioned centers (Asia: n=119, 21.0%, Europe:
n=55, 9.7%, and North America: n=393, 69.3%) with cuta-
neous involvement during the course of LE were included
in the study. Only patients with active skin lesions were
included. Diagnosis of CLE has been established based on
clinical manifestation and skin biopsy, if necessary. Only
patients with CLE specific lesions were included into this
study according to Sontheimer [1] andKuhn et al. [2]. Patients
with other skin diseases, which might influence the achieved
results, were excluded.
All patients agreed to participate in the study. Their age
ranged between 18 and 89 years (mean 41.4 ± 13.2 years),
and 472 patients (83.2%) were women. Among analyzed
subjects, 330 (58.2%) patients were diagnosed as having
CCLE (including 302 patients with DLE, 14 patients with
LEP, 11 patients with HLE, and 3 patients with CHLE), 123
(21.7%) as having SCLE, 78 (13.8%) as having ACLE, and
36 (6.3%) with ICLE (LET). The mean disease duration
was 9.8 ± 11.2 years. The disease activity and damage
of CLE were assessed according to the Cutaneous Lupus
Erythematosus Disease Area and Severity Index (CLASI)
[11].
2.2. Study Instruments and Assessments. The current report
describes results on the evaluation of prevalence and severity
of pruritus in CLE patients being a prerequisite for fur-
ther investigation focusing on the clinical manifestation of
pruritus in CLE patients and its influence on the patients’
quality of life. After receiving a formal approval to par-
ticipate and collecting basic demographic data, all patients
with CLE were asked whether they suffer from pruritus
or not. Only patients with pruritus lasting ≥6 weeks were
considered as positive. If the answer was “yes”, the patient
was asked to assess the average severity of pruritus within
the previous 3 days using the Numerical Rating Scale from
0 to 10. All patients were instructed that 0 means no itch
while 10 means the worst imaginable itch. Subsequently,
pruritus intensity was categorized with the following cut-off
values: 0 points: no pruritus, 1-3 points: mild pruritus, 4-
6 points: moderate pruritus, and 7-10 points: severe pruri-
tus.
2.3. Statistical Analysis. All results were analyzed statistically
using Statistica 12.0 (Statsoft, Krakow, Poland). Descriptive
statistics included frequencies, mean, standard deviation,
median,minimal, andmaximal values.The significance of the
observed differences between groups has been determined
by Mann–Whitney U test or 𝜒2 test with Yates correction,
where necessary. Correlation between studied parameters
were verified with Spearman rank correlation test. A 𝑝
value lower than 0.05 was considered as statistically signifi-
cant.
BioMed Research International 3
Table 1: Intensity of pruritus in various subtypes of chronic cutaneous lupus erythematosus.
No pruritus Mild pruritus Moderate pruritus Severe pruritus
Localized discoid lupus erythematosus 19,5% 61.5% 12.2% 6.8%
Generalized discoid lupus erythematosus 24,7% 29.9% 26.8% 18.6%
Lupus erythematosus profundus 42,9% 35.7% 14.3% 7.1%
Hypertrophic lupus erythematosus 0% 45.4% 27.3% 27.3%
Chilblain lupus erythematosus 0% 100% 0% 0%
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Figure 1: Prevalence of pruritus in various subtypes of cutaneous
lupus erythematosus (p=0.002).
3. Results
3.1. Prevalence of Pruritus in CLE Subtypes. Pruritus was
present in 425 of all analyzed patients (75.0%). It wasmost fre-
quently reported by subjects with ACLE (82.1%), followed by
CCLE (78.8%), SCLE (65.9%), and ICLE (55.6%) (p<0.001).
According to the International Forum for the Study of Itch
classification [3], pruritus in CLE subjects was considered as
dermatological one. In 85.1% of patients pruritus was limited
to the skin lesions, while in 14.9% also uninvolved skin was
itchy.
3.2. Severity of Pruritus in CLE Subtypes. Based on the NRS,
the severity of itch was mild, moderate, and severe in 264
(62.1%), 98 (23.1%), and 63 (14.8%) patients reporting this
symptom, respectively.With regard to the specific subtypes of
CLE, inACLEmild pruritus was found in 50 (64.1%) patients,
moderate in 8 (10%), and severe in 6 (7.5%), and in SCLE
mild pruritus was reported by 35 (28.5%) patients, moderate
by 28 (22.8%), and severe by 18 (14.6%), and in CCLE mild
pruritus was found in 168 (50.9%) patients, moderate in 56
(17%), and severe in 36 (10.9%), while among ICLE subjects
mild pruritus was reported by 11 (30.6%) patients, moderate
by 6 (16.7%), and severe by 3 (8.3%), respectively (p=0.002)
(Figure 1). A significant correlation was observed between
pruritus intensity and activity of skin lesions according to
CLASI (𝜌=0.45, p<0.001), but not with the skin damage
scoring (𝜌=-0.07, p=0.51). The age and CLE duration did not
influence significantly the pruritus intensity reported by the
patients (𝜌=-0.06, p=0.58 and 𝜌=-0.16, p=0.13, respectively).
3.3. Severity of Pruritus in CCLEVariants. Theseverity of itch
among subjects with localized DLE was mild in 126 (61.5%)
patients, moderate in 26 (12.2%), and severe in 14 (6.8%).
Among subjects with generalized DLE, the severity of itch
was mild in 29 (29.9%) patients, moderate in 26 (26.8%), and
severe in 18 (18.6%). Among subjects with LEP, the severity
of itch was mild in 5 (35.7%) patients, moderate in 2 (14.3%)
patients, and severe in 1 (7.1%) patient, while in HLE the
severity of itch was mild in 5 (45.4%) patients and moderate
and severe in 3 (27.3% each) (Table 1). All 3 subjects with
CHLE reported mild pruritus (p<0.001).
3.4. Mean Pruritus Intensity. The highest mean NRS value
was reported by subjects with HLE (5.1±3.0 points) followed
by generalized DLE (3.6±3.0 points), SCLE (3.0±3.0 points),
CHLE (3.0±1.0 points), localizedDLE (2.6±2.0 points), ICLE
(2.6 ± 3.0 points), ACLE (2.5 ± 1.2 points), and LEP (1.9 ± 2.7
points) patients.
4. Discussion
Our data suggests that pruritus is indeed a common subjec-
tive symptom of CLE, as it was present on average in 3 out
of 4 patients included in our study, albeit, in general, it was
of mild severity. The prevalence of severe pruritus was about
10% depending on CLE subtypes. Similarly, Kapadia and
Haroon [8] studied Indian patient population with systemic
LE (SLE) and confirmed that itch was a frequent feature
of the disease with a reported prevalence of 45%. However,
the study had a major limitation since it only included
patients with SLE rather than those with CLE. In addition,
the groups were not diversified based on LE-specific and
LE-nonspecific lesions, making it impossible to establish the
possible relation of pruritus to the presence, pattern, and
intensity of cutaneous involvement [8]. On the other hand,
Goreshi et al. [9] investigated QoL in DM in comparison to
CLE and found the severity of itch to be higher in DM than
in CLE. They suggested that in certain cases the presence
of pruritus should exclude the diagnosis of CLE rather than
confirm it. This conclusion suggested that itch is not a major
complaint in CLE. This study did not, however, provide
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information about the prevalence of pruritus in these subsets
of patients [9]. An interesting, yet rather small observational
study was performed in CLE subjects treated at the Hospital
of the University of Pennsylvania, Philadelphia. The aim was
to measure the correlation of change in Cutaneous Lupus
Erythematosus Disease Area and Severity Index (CLASI)
with the change in patients’ assessments of pain and pruritus
14 weeks after starting a new standard of care therapy.
However, the correlation of CLASI score with the patient’s
assessment of itch level was only moderate. Not every patient
complained of itch, and some patients actually developed
this symptom independently of the skin condition and the
treatment. Therefore, the authors concluded that as it did
not reflect disease progression or severity, it was unlikely
that pruritus could be a part of reliable disease activity
measurement in CLE [11]. A more recent study performed
by Me´ndez-Flores et al. [12] found no difference in pruritus
score between patients who had CLE, LE-nonspecific skin
manifestations, or a combination of the two. However, the
authors found a median pruritus VAS score of 6 points in
the LE-specific disease group, 4 points in the LE-nonspecific
disease group, and 6.5 points in the combination group.
Although the differences in scores between groups were
not significant, these data do suggest that patients with LE-
specific skin disease in particular do experience a moderate
level of pruritus. Additionally, in the group with LE-specific
lesions, the pruritus score and the CLASI activity score were
correlated (p=0.01), suggesting that itch is a symptom of
active CLE lesions. However, in this study, pain but not itch
intensity was significantly correlated with QoL [12].
Comparing our observations with the available data on
the frequency of itching in other connective tissue diseases,
we can state that this symptom is substantiallymore prevalent
in CLE than in SLE (45%) and SSc (43%). Much to our
surprise, its frequency was even comparable to pruritus
prevalence observed in other studies on psoriasis (70-90% of
patients), late stage cutaneous T cell lymphoma (83%) [13], or
chronic idiopathic urticaria (79%) [6]. Considering a small
number of systematic studies on CLE that include pruritus
as one of the evaluated domains, and a lack of research
dedicated exclusively to the assessment of itch qualities in
these patients, it seems to be a frequently overlooked and/or
underappreciated symptom of this condition. Based on our
results we may state that the highest prevalence rate of
pruritus was observed in subjects with ACLE. Assumption
that in the most inflammatory skin phenotype the presence
of itch is a reflection of more active cutaneous lesions would
be the most obvious explanation of the highest itch preva-
lence in subjects suffering from this particular CLE subtype.
Surprisingly, it stands in contradiction to the other published
results that show a relatively low prevalence of pruritus in
SLE patients [8, 14]. Nonetheless, CCLE sufferers reported
pruritus surprisingly often, which was also contradictory
to our expectations. However, numerous case reports and
review articles on this CLE variant mention pruritus, along
with pain, as accompanying symptom of the disease. One
of the hypotheses that would explain the high prevalence of
these symptoms in this particular CLE subtype is the com-
pression of cutaneous nerves secondary to dermal fibrosis, in
amanner somewhat similar to that observed in late stage SSc.
ICLE patients complained of itching significantly less often
than CCLE subjects (55,6% versus 78,8%). This observation,
among other distinct features of ICLE and its differences from
CCLE, may serve as another point for including ICLE as a
separate (fourth) subtype of CLE, as proposed by A. Kuhn et
al. [2]. Of note, more recent studies have shown a pathogenic
role of interleukin 18 (IL-18) [15] in CLE and significance
of toll-like receptor 7 (TLR7) [16] in SLE. Both proteins are
known to play a role in the induction of pruritus [17, 18].
Several limitations should be considered when interpret-
ing the results of this study. The major one is a lack of
longitudinal prospective design and that the patients were
assessed in different stages of treatment which could have
influenced their responses regarding pruritus. Some medica-
tions can affect the intensity of itching that is experienced
by patients. Another contribution to the possible bias of
the results could be the fact that most of the patients were
treated in highly specialized academic centers. It is thus
possible that these patients seek treatment or were referred
due to earlier therapeutic difficulties, possibly with pruritus
as more prominent symptom than in less selective patient
population. However, our study required participation of
physicians qualified and experienced in treating CLE patients
who are usually linked to academic centers. Finally, lack of
a control group is another limitation which precluded us
to compare the prevalence of pruritus in CLE patients with
reference to the general population.
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